TICAGRELO 60MG TABLETS (EACH CONTAINS TICAGRELO 60MG
TICAGRELO
What it does
Ticagrelo is a medication used to prevent blood clots and reduce the risk of heart problems.
Commonly used for: preventing blood clots, reducing the risk of heart attack, reducing the risk of stroke
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.
Sourcing - Kenya onlyRegistration & product details
Source: Food and Drugs Authority · fetched 2026-05-22 02:34:41 · updated 2026-10-20 04:00:08
About this medicine
Ticagrelo is a medication used to prevent blood clots and reduce the risk of heart problems.
What it treats
- preventing blood clots
- reducing the risk of heart attack
- reducing the risk of stroke
How it works
Ticagrelo works by making it harder for platelets in your blood to stick together, which helps to prevent clots from forming.
Who it's for
This medication is for adults who have had a heart attack or severe chest pain, or those at high risk of heart problems.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: ticagrelo
Ticagrelor is an oral antiplatelet medication that inhibits platelet aggregation, primarily used to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS) and those with a history of myocardial infarction (MI). It is a reversible antagonist of the P2Y12 receptor on platelets, leading to decreased platelet activation and aggregation.
Indications
- Acute coronary syndrome (ACS)
- History of myocardial infarction (MI)
- Prevention of thrombotic cardiovascular events
Dosage
Children: Ticagrelor is not approved for use in children, refer to the BNF for Children for any potential pediatric dosing considerations.
Adults: The standard adult dose of ticagrelor is 180 mg orally as a loading dose, followed by 90 mg twice daily.
Mechanism of action
Ticagrelor works by reversibly binding to the P2Y12 receptor, a subtype of the adenosine diphosphate (ADP) receptor, inhibiting the ADP-mediated activation of the GPIIb/IIIa receptor complex. This action effectively prevents the aggregation of platelets and formation of thrombi, which are crucial steps in the pathophysiology of thrombosis and cardiovascular events.
Pharmacodynamics
The pharmacodynamic effects of ticagrelor include rapid onset of action after administration, with significant platelet inhibition observed within 30 minutes. The drug exhibits dose-dependent effects, with higher doses correlating with greater platelet inhibition. The antiplatelet effect persists for several days after discontinuation, and the degree of platelet inhibition can be monitored by assessing platelet aggregation tests.
Pharmacokinetics
Ticagrelor is rapidly absorbed after oral administration, with peak plasma concentrations occurring within 1.5 to 3 hours. It has a bioavailability of approximately 36% due to extensive first-pass metabolism. The drug is primarily metabolized by cytochrome P450 enzymes, mainly CYP3A4 and CYP3A5, and has a half-life of about 7 hours. Ticagrelor is excreted predominantly in the feces, with renal excretion accounting for a smaller fraction of the dose.
Contra-indications
- Active bleeding
- History of intracranial hemorrhage
- Severe hepatic impairment
- Hypersensitivity to ticagrelor or any excipient
Adverse effects
- Bleeding complications
- Dyspnea
- Bradycardia
- Gastrointestinal bleeding
- Elevated serum creatinine
- Nausea
- Headache
- Rash
Interactions
- cobicistat+ticagrelor: Severe (increases exposure)
- idelalisib+ticagrelor: Severe (increases exposure)
- mitotane+ticagrelor: Severe (decreases exposure)
- rifampicin+ticagrelor: Severe (decreases exposure)
- amiodarone+ticagrelor: Moderate (increases exposure)
- cenobamate+ticagrelor: Moderate (decreases exposure)
- ciclosporin+ticagrelor: Moderate (increases exposure)
- azithromycin+ticagrelor: Moderate (increases exposure)
- ranolazine+ticagrelor: Moderate (increases exposure)
- ticagrelor+dabigatran: Moderate (increases exposure)
Precautions
- Monitor for signs of bleeding
- Use caution in patients with renal impairment
- Consider risks in patients undergoing surgery
- Assess for respiratory issues due to dyspnea
Pregnancy
Use only if the benefits outweigh the risks, as there is limited data on safety.
Breast-feeding
Not recommended, as it is not known whether ticagrelor is excreted in human milk.
Storage
Store at room temperature, away from moisture and heat.
Formulations
- Tablets: 60 mg, 90 mg
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
This drug in other countries
The same active ingredient registered across other registries we cover - including different brands.